Lakefront Sells Preclinical CAR-T Pipeline in Cell Therapy Exit

Lakefront sells preclinical cell therapy pipeline

Belgian biotech Lakefront Biotherapeutics has sold its preclinical cell therapy pipeline, according to Thepharmaletter. The publisher reported that the transaction gives the programs a route forward as Lakefront completes its exit from the cell therapy field.

Thepharmaletter described Lakefront as formerly Galapagos and identified the company as listed on Euronext under LKFT. Its report characterized the divested assets as CAR-T programs.

The buyer is a new company co-founded by Paul Stoffels, Lakefront’s former chief executive, Thepharmaletter reported. The supplied report does not provide additional transaction terms.

Programs move to a new company

Under the reported sale, Lakefront’s preclinical CAR-T programs will continue with the new company co-founded by Stoffels. Thepharmaletter framed the transaction as part of Lakefront’s move away from cell therapy.

The development centers on the separation of a preclinical pipeline from a company exiting the therapeutic field. For pharmaceutical and biotech sales professionals, the reported transaction identifies a change in where these CAR-T programs will be managed as Lakefront completes its stated exit.

Related investment referenced by Thepharmaletter

Thepharmaletter’s headline also reported that Mankind agreed an investment in Armed Cell. The supplied report does not provide further details about that agreement.

• Lakefront Biotherapeutics: The Belgian biotech selling its preclinical cell therapy pipeline.
• Paul Stoffels: Former Lakefront chief executive and co-founder of the new company receiving the programs.
• Mankind and Armed Cell: Companies named by Thepharmaletter in connection with an agreed investment.

The reported outcome is that Lakefront’s preclinical CAR-T pipeline has a route forward with the new company while Lakefront completes its exit from cell therapy.